Equities analysts predict that Natera Inc (NASDAQ:NTRA) will report earnings per share (EPS) of ($0.53) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Natera’s earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.44). Natera reported earnings per share of ($0.52) during the same quarter last year, which indicates a negative year over year growth rate of 1.9%. The company is scheduled to announce its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Natera will report full-year earnings of ($2.05) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.90). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.94) per share, with EPS estimates ranging from ($1.09) to ($0.71). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Natera.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, May 8th. The medical research company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.01). The business had revenue of $62.34 million for the quarter, compared to analyst estimates of $54.86 million. Natera had a negative return on equity of 752.93% and a negative net margin of 58.84%. The company’s revenue for the quarter was up 26.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.70) EPS.
A number of research firms have recently commented on NTRA. ValuEngine raised Natera from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Morgan Stanley raised their price target on Natera from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 9th. BidaskClub raised Natera from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Craig Hallum began coverage on Natera in a research report on Monday, April 9th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Zacks Investment Research lowered Natera from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Natera presently has a consensus rating of “Buy” and an average target price of $14.80.
Shares of Natera traded up $0.09, reaching $11.74, during mid-day trading on Monday, according to Marketbeat Ratings. 153,851 shares of the company’s stock were exchanged, compared to its average volume of 138,435. The firm has a market cap of $635.07 million, a P/E ratio of -4.89 and a beta of 2.07. The company has a debt-to-equity ratio of -18.90, a current ratio of 1.80 and a quick ratio of 1.68. Natera has a twelve month low of $7.78 and a twelve month high of $14.76.
In related news, major shareholder Claremont Creek Partners Fund sold 37,540 shares of Natera stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $11.48, for a total value of $430,959.20. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders sold 66,013 shares of company stock worth $754,586. 13.18% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Trexquant Investment LP acquired a new stake in Natera in the 1st quarter valued at approximately $119,000. MetLife Investment Advisors LLC acquired a new stake in Natera in the 4th quarter valued at approximately $124,000. Jefferies Group LLC acquired a new stake in Natera in the 4th quarter valued at approximately $130,000. A.R.T. Advisors LLC acquired a new stake in Natera in the 1st quarter valued at approximately $164,000. Finally, Wells Fargo & Company MN increased its position in shares of Natera by 69.2% during the 3rd quarter. Wells Fargo & Company MN now owns 30,504 shares of the medical research company’s stock worth $393,000 after purchasing an additional 12,473 shares during the last quarter. 72.28% of the stock is currently owned by institutional investors and hedge funds.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Get a free copy of the Zacks research report on Natera (NTRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.